针对B细胞淋巴瘤的T细胞参与抗体
1Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Seminars in hematology
|January 15, 2026
概括
参与T细胞的双特异性抗体 (BsAbs) 正在彻底改变B细胞淋巴瘤治疗. 本综述详细介绍了四个CD20 × CD3 BsAbs和一个CD19 × CD3 BsAb,总结了它们的疗效,安全性以及对细胞因子释放综合征等副作用的管理.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 血液学 血液学 血液学
背景情况:
- 参与T细胞双特异性抗体 (BsAbs) 已经显著推进了B细胞非霍奇金淋巴瘤治疗.
- 已批准的CD20 × CD3 BsAbs包括mosounetuzumab (FL),glofitamab (DLBCL) 和epcoritamab/odronextamab (FL/DLBCL) 等药物.这些药物中使用的BsAbs中包括mosounetuzumab (FL),glofitamab (DLBCL) 和epcoritamab/odronextamab (DLBCL).
- 苏罗瓦塔米格 (CD19 × CD3 BsAb) 在复发性/耐药性B细胞淋巴瘤中显示出有前途.
研究的目的:
- 审查CD20 × CD3和CD19 × CD3BsAbs在B细胞淋巴瘤中的疗效和安全性.
- 为了比较不同的 BsAbs 关于开发平台,结构和管理路线.
- 总结剂量,副作用管理和正在进行的临床评估.
主要方法:
- 对四个CD20 × CD3 BsAbs和一个CD19 × CD3 BsAb的临床数据的审查.
- 对B细胞淋巴瘤亚型的疗效分析.
- 对安全性概况的评估,包括细胞因子释放综合征 (CRS) 和免疫效应细胞相关的神经毒性综合征 (ICANS).
主要成果:
- CD20 × CD3 BsAbs被批准用于FL和DLBCL的第三线治疗.
- CRS发生在近一半的患者身上,大多数是低级的,有各种各样的缓解策略.
- ICANS的发病率一般低于10%,罕见的严重事件.
- 目前正在进行的研究正在探索这些药物在前线和复发/耐药环境中,作为单一疗法或组合疗法.
结论:
- BsAbs代表了B细胞淋巴瘤的显著治疗进展.
- 了解每个BSAb的不同配置和安全管理对于最佳的患者护理至关重要.
- 进一步的研究正在评估BsAbs在早期治疗线和组合疗法中.
相关概念视频
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
B Cell Activation and Differentiation
16.1K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
16.1K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
T Cell Activation and Clonal Selection
14.8K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
14.8K
Cytotoxic T Cells-mediated Immune Response
6.5K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.5K
Special Features of Adaptive Immunity
2.9K
The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
2.9K


